Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT was delisted on the 31st of December, 2020.
571 hedge funds and large institutions have $1.18B invested in Bristol-Myers Squibb Company Contingent Value Rights in 2020 Q3 according to their latest regulatory filings, with 68 funds opening new positions, 120 increasing their positions, 186 reducing their positions, and 75 closing their positions.
2,672% more call options, than puts
Call options by funds: $15.5M | Put options by funds: $560K
9% less first-time investments, than exits
New positions opened: 68 | Existing positions closed: 75
2% less funds holding
Funds holding: 583 → 571 (-12)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
35% less repeat investments, than reductions
Existing positions increased: 120 | Existing positions reduced: 186
37% less capital invested
Capital invested by funds: $1.89B → $1.18B (-$706M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$48.3M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$44.1M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$22.1M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$20.3M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$44.2M |
| 2 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$27.6M |
| 3 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
-$24M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$17M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$15.7M |
BMY.RT Hedge Fund Activity: Q3 2020 in Review
571 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q3 2020, worth a combined $1.18B — down 37% from $1.89B a quarter earlier.
Sellers outnumbered buyers: 75 funds closed out of BMY.RT and 68 opened new positions — a net loss of 7 holders — while 186 trimmed existing stakes and 120 added.
The largest buyer was Avidity Partners Management, adding an estimated $48.3M. The largest seller was Pentwater Capital Management, cutting an estimated $44.2M.
- 571 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q3 2020, down from 583 in Q2 2020.
- Funds reported $1.18B of Bristol-Myers Squibb Company Contingent Value Rights stock for Q3 2020, down 37% quarter-over-quarter.
- 68 funds opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q3 2020 and 75 closed out, a net change of -7 holders.
- The largest Bristol-Myers Squibb Company Contingent Value Rights buyer in Q3 2020 was Avidity Partners Management, an estimated $48.3M added.
- The largest Bristol-Myers Squibb Company Contingent Value Rights seller in Q3 2020 was Pentwater Capital Management, an estimated $44.2M sold.
Based on aggregated 13F filings for Q3 2020.